Investor Relations

Investing in Lucid Diagnostics is investing in innovation that has the potential to impact and even transform healthcare.

Company Overview

Lucid Diagnostics Inc., markets the first and only commercial tools for widespread early detection of esophageal precancer and cancer – the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device.

Stock Information
Market Cap
Stock Information

Latest News & Updates

May 13, 2024

Quarterly EsoGuard® test volume increased 10 percent Strengthened balance sheet following completion of $29.8 million Series B Preferred Stock Offering MolDX pre-submission meeting scheduled for...

May 9, 2024

EsophaCap device recalled due to recent publication of serious device failures Lucid Diagnostics' EsoCheck® unaffected by recall and remains the gold standard for non-endoscopic cell collection...

May 7, 2024

Final closing yields total gross proceeds of $29.8 million from offering Mr. Matheis serves as President and CEO of Sentara Health, one of the largest not-for-profit integrated health systems in...